Lilly’s Alzheimer Drug Not in Late-Stage Forecast
Playing the usual pharma parlor game, John Carroll at FierceBiotech offers his top-10 drugs in the late-stage pipeline. Five are oncologic products, and two are indicated for hepatitis C. Carroll wisely omits solanezumab, Lilly’s quixotic* gamble on a disease-modifying drug for Alzheimer disease, but forecasts “major league potential” for Lilly’s dulaglutide, another GLP-1 compound for diabetes.
* Hey, we both can use the word. Chug!
A native East Tennessean, Barbara Martin is a formerly practicing, board-certified neurologist who received her BS (psychology, summa cum laude) and MD from Duke University before completing her postgraduate training (internship, residency, fellowship) at the Hospital of the University of Pennsylvania in Philadelphia. She has worked in academia, private practice, medical publishing, drug market research, and continuing medical education (CME). For the last 3 years, she has worked in a freelance capacity as a medical writer, analyst, and consultant. Follow Dr. Barbara Martin on Google + and Twitter.
